Changeflow GovPing Pharma & Healthcare Oxidative Stress in Autoimmune Rheumatic Diseases
Routine Notice Added Final

Oxidative Stress in Autoimmune Rheumatic Diseases

Favicon for changeflow.com ClinicalTrials.gov Studies
Published
Detected
Email

Summary

NIH National Library of Medicine registered an observational study (NCT07536529) examining oxidative stress markers in autoimmune rheumatic diseases including rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. The study measures blood and tissue redox status to understand free radical impact on biomolecules in inflammatory joint disease patients. This registry entry applies to clinical investigators and healthcare providers involved in the study.

Published by NIH on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

NIH National Library of Medicine registered a new observational study on ClinicalTrials.gov to examine oxidative stress markers in patients with autoimmune rheumatic diseases including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and systemic lupus erythematosus. The study investigates the disturbance of blood and tissue redox status due to excessive free radical production and its impact on biomolecules including proteins, lipids, and DNA. This registry entry provides transparency on ongoing clinical research but does not create compliance obligations for any regulated parties. Healthcare providers and clinical investigators conducting the study must follow standard research protocols and IRB requirements, while other entities are not affected by this registration notice.

Archived snapshot

Apr 18, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← ClinicalTrials.gov Studies

Oxidative Stress in Autoimmune Rheumatic Diseases

Observational NCT07536529 Kind: OBSERVATIONAL Apr 17, 2026

Abstract

Rheumatic diseases constitute a group of non-communicable diseases characterized by chronic inflammation. The most common autoimmune rheumatic diseases (ARDs) are rheumatoid arthritis, psoriatic arthritis, systemic lupus erythematosus, myositis, Sjogren's syndrome and systemic scleroderma. These autoimmune disorders lead to joint destruction and adversely influence the human body systemically. One of their characteristics is comorbidity, since patients usually suffer also from other pathologies such as cardiovascular diseases and obesity. In addition, their treatment requires a combination of both biological and conventional pharmaceutical interventions as well as other parameters such as physical activity programs, nutrition, and the use of smart electronic devices. Therefore, the ARDs burden health systems worldwide. Apart from the physiological manifestations of ARDs, specific changes are observed at the cellular and molecular level. A common biochemical/molecular symptom of these diseases is oxidative stress. This condition leads to the disturbance of blood and tissue redox status due to the excessive production of free radicals. Given that free radicals are highly reactive moieties with strong oxidative capacity against biomolecules (i.e., proteins, lipids, DNA), they compromise the efficacy of the intrinsic antioxidant mechanisms and, finally, induce the disruption of redox homeostasis. However, there is no sufficient data linking the levels of redox status of patien...

Conditions: Inflammatory Joint Diseases, Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS)

View original document →

Get daily alerts for ClinicalTrials.gov Studies

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from NIH.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
NIH
Published
April 17th, 2026
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
NCT07536529

Who this affects

Applies to
Healthcare providers Clinical investigators
Industry sector
6221 Hospitals & Health Systems
Activity scope
Clinical trial registration Observational study
Geographic scope
United States US

Taxonomy

Primary area
Healthcare
Operational domain
Clinical Operations
Topics
Pharmaceuticals Public Health

Get alerts for this source

We'll email you when ClinicalTrials.gov Studies publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!